Phase 4
N=180
New Stage 1 Formula on Gut Comfort and Gut Health
Health Behavior
Bottom Line
View on ClinicalTrials.gov: NCT02406937 ↗Enrolled (actual)
180
Serious AEs
0.0%
Results posted
Oct 2016
Primary outcome: Primary: Stool Frequency — 2.2; 2.2; 2.3; 1.6 Times per day
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Oral intake of Feihe New Formula (Dietary_supplement); Oral intake of Feihe Stage 1 Formula (Dietary_supplement); Breast Feeding (Dietary_supplement)
- Age
- Pediatric · 0+ yrs
- Sex
- All
- Sponsor
- Heilongjiang Feihe Dairy Co. Ltd.
- Primary completion
- Aug 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Stool Frequency |
2.2; 2.2; 2.3; 1.6; 1.8; 2.1 | — |
| SECONDARY Number of Participants With Gastrointestinal Symptoms |
0; 0; 0 | — |
| SECONDARY Stool Consistency |
3.61; 3.74; 3.76; 3.19; 3.59; 3.73 | — |
| SECONDARY Crying Time |
2.98; 2.90; 2.92; 3.43; 2.69; 2.62 | — |
| SECONDARY Fecal Concentration of Short Chain Fatty Acid |
4.66; 4.75; 4.72; 1.28; 1.27; 1.33 | — |
| SECONDARY Body Length |
56.9; 57.7; 57.8; 60.3; 60.8; 61.1 | — |
| SECONDARY Number of Participants With Eczema |
15; 9; 8 | — |
| SECONDARY Fecal Laboratory Detection for sIgA |
53.8; 53.0; 55.5; 55.3; 62.7; 65.9 | — |
| SECONDARY Fecal Bacterium Concentration |
7.56; 7.55; 7.58; 6.61; 6.58; 6.63 | — |
| SECONDARY Eczema Duration |
62.1; 45.2; 38.6 | — |
| SECONDARY Body Weight |
5191.5; 5291.5; 5462.1; 6142.4; 6251.7; 6370.7 | — |
| SECONDARY Head Circumference |
38.5; 38.7; 39.0; 39.9; 40.1; 40.4 | — |
| SECONDARY Chest Circumference |
36.9; 37.2; 37.3; 38.2; 38.6; 38.7 | — |
| SECONDARY Milk Regurgitation Frequency |
2.68; 2.47; 2.43; 2.70; 2.02; 1.89 | — |
| SECONDARY Milk Feeding Quantity |
732.1; 742.2; 750.7; 928.6; 936.3; 946.0 | — |
| SECONDARY Sleeping Time |
18.0; 17.8; 17.9; 17.6; 17.4; 17.6 | — |
| SECONDARY Body Mass Index (BMI) |
15.9; 15.8; 16.2; 16.9; 16.9; 17.0 | — |
Summary
180 qualified subjects aged from 7 days to 90 days will be enrolled with the 144 completed in study (allowing for a 20% drop-out rate). Subjects will be randomly assigned into 3 groups, including breast feeding, commercial and new formula group. Study intervention is 12 weeks.
Eligibility Criteria
Inclusion Criteria
- Infants aged 7-90 days;
- Fed by breast milk before enrollment;
- Parent or legal guardian fully understand the purpose and requirement, including the potential risks and side effects of the study;
- Willing to participate in the study and comply all the procedures;
- Concent form signed by parents.
Exclusion Criteria
- Twins, multiple birth, low birth weight children, over birth weight children or early birth children with gestational age less than 37 weeks;
- Think about the need to exclude C-section delivered infants? It's often the majority of births in Chinese tier-1 cities, so it will probably make the study recruitment slower, and postpone the study. The microflora of C-section infants in known to be different compared to normally born infants. At least, the mode of delivery should be noted and calculated into the primary and secondary outcome measurements as a potential confounding factor
- During pregnancy, the mothers had pregnancy complications or other disease that may affect the results;
- Having serious diseases that may affect study interventions, such as neonatal sepsis, pneumonia (associated with respiratory failure), heart failure and other disease;
- Having neonatal diarrhea or acute respiratory infections within 48hours before enrollment;
- Having potential metabolic diseases, chronic diseases, congenital malformations, central nervous system disorders, neuromuscular disorders or diseases affecting bone metabolism that may affect growth or the study results;
- Having taken any food containing prebiotics or probiotics tithing 15 days of enrollment;
- Having gluten allergy (celiac disease);
- Body weight-to-height Z-value<-3 according to the standard of WHO;
- Receiving hormone therapy and intravenous nutrition;
- Lactose intolerance or allergic to ingredients of study product;
- Have participated in other clinical studies within 3 months prior to the date of screening;
- Unable to comply the study schedule.
Data sourced from ClinicalTrials.gov (NCT02406937). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.